Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994705 · ClinicalTrials.gov registry record · Phase 1
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03994705 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT03994705, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Descartes-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03994705
The ClinicalTrials.gov registry entry for NCT03994705 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03994705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03994705 about?
NCT03994705 is a clinical study titled "Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma". This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
What is the current status of trial NCT03994705?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-01. Estimated completion is 2021-06-11.
What interventions are being tested in trial NCT03994705?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Descartes-11 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03994705?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.